NCT07252141Not yet recruiting
miR-101-3p and Autotaxin in SLE Patients
Association Between the Expression Levels of MicroRNA-101-3p and Autotaxin in Serum of Systemic Lupus Erythematosus Patients
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organs and characterized by heterogeneous clinical manifestations. This case-control study aims to assess the association between serum expression levels of MicroRNA-101-3p and Autotaxin (ATX) in SLE patients compared with healthy controls. The hypothesis is that dysregulation of miR-101-3p and ATX contributes to SLE pathogenesis and may serve as potential non-invasive biomarkers for disease activity and prognosis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 30 Dec 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Eman Mohamed Shawky
- Diseases
- Lupus (SLE)
- NCT number
- NCT07252141
What you commit to
- Study type: Observational
- Planned participants: 40
- From 30 Dec 2025 to the primary completion date, 30 Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active infections or malignancy
- Co-existing autoimmune diseases
Other
- Pregnancy or lactation
- Refusal to participate
Who the study is looking for
- Study Population: Adult patients diagnosed with systemic lupus erythematosus and healthy matched controls.
- \- Age ≥ 18 years
- Diagnosis of SLE according to 2012 SLICC criteria
- Willingness to participate and provide informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.